文献速递前列腺癌

PROBASE试验:MRI质量与读片经验对前列腺癌筛查的影响

MRI Quality and Reader Experience in Organized Prostate Cancer Screening: Insights from the PROBASE Trial.
PubMed 文献 · Eur Urol Oncol · 2026-06-01

该研究基于PROBASE筛查试验,分析516例PSA≥3 ng/ml后接受多参数MRI及联合活检的男性,比较本地与专家参考读片对临床显著前列腺癌(csPCa)检出的影响。结果显示参考读片提高了阴性预测值(92% vs 86%)、阳性预测值(57% vs 50%)和敏感性(83% vs 69%),低MRI质量(PI-QUAL 1-3/5)与csPCa检出率降低(46% vs 62%)相关。

要点

  • 专家参考读片较本地读片提高csPCa检出敏感性(83% vs 69%)和阴性预测值(92% vs 86%)。
  • 低MRI质量(PI-QUAL 1-3/5)与csPCa检出率降低(46% vs 62%)和真阴性率降低(84% vs 95%)相关。
  • 未来MRI筛查策略应纳入高质量成像、标准化协议和有经验的读片。

核心结论

  • 专家参考MRI读片可显著提高筛查场景下csPCa检出并减少不必要的活检。

研究设计与样本

  • PROBASE试验的预定义亚组分析,纳入516例PSA≥3 ng/ml后接受多参数MRI及联合MRI靶向和系统活检的男性。

主要发现

  • 参考读片较本地读片提高NPV(92% vs 86%)、PPV(57% vs 50%)和敏感性(83% vs 69%)。
  • 本地读片在PI-RADS 1-2中漏诊更多csPCa(17.1% vs 2.9%),在PI-RADS 4-5中假阳性更多(76例 vs 59例)。
  • 低MRI质量(PI-QUAL 1-3/5)与csPCa检出率降低(46% vs 62%)和真阴性率降低(84% vs 95%)相关。
  • PI-QUAL在各研究中心间存在差异。
  • 参考读片的PI-RADS分类漏诊了小或弥漫浸润性csPCa,常发生于较低质量扫描。

关键数值与推荐

  • 活检阈值设定为PI-RADS评分≥4。
  • csPCa定义为国际泌尿病理学会分级≥2。
  • MRI质量采用PI-QUAL(v1)评估。

临床怎么用

  • 在MRI筛查中应优先保障高质量成像、标准化协议和有经验的读片。
  • 专家参考读片可作为提高csPCa检出和减少不必要活检的质量控制措施。

局限性

  • 使用本地解读定义活检靶点,限制了回顾性比较。
  • 可能低估了参考读片者的性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The diagnostic performance of prostate magnetic resonance imaging (MRI) critically depends on image quality and reader expertise. The PROBASE trial is a prospective population- and prostate-specific antigen (PSA)-based prostate cancer (PCa) screening study enrolling men aged 45 yr. OBJECTIVE: In this predefined substudy, we evaluated the impact of MRI quality and expert reference reading on clinically significant PCa (csPCa; International Society of Urological Pathology grade ≥2) detection. DESIGN, SETTING, AND PARTICIPANTS: This analysis included 516 participants who underwent multiparametric MRI and combined MRI-targeted biopsy and systematic biopsy after screening with PSA ≥3 ng/ml. Local Prostate Imaging Reporting and Data System (PI-RADS) scores were compared with reference readings by experienced uroradiologists. MRI quality was assessed using Prostate Imaging Quality (version 1; PI-QUAL [v1]). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Detection rates, positive predictive values (PPV), and negative predictive values (NPV) were calculated at an underlying biopsy threshold of PI-RADS score of ≥4. Image quality was compared between the study sites. RESULTS AND LIMITATIONS: Reference reading yielded higher NPV (92% vs 86%), PPV (57% vs 50%), and sensitivity (83% vs 69%) than local reading. Local reading missed substantially more csPCa in PI-RADS 1-2 (17.1% vs 2.9%) and resulted in more false-positive MRI findings in PI-RADS 4-5 (n = 76 vs n = 59) than reference reading. Lower MRI quality (PI-QUAL 1-3/5) was associated with reduced csPCa detection (46% vs 62%) and true negative rate (84% vs 95%). PI-QUAL differed between the study sites. PI-RADS classification of reference reading missed small or diffusely infiltrative csPCa, often in lower quality scans. Limitations include using local interpretations to define biopsy targets, limiting retrospective comparison, and possibly underestimating reference-reader performance. CONCLUSIONS: Expert reference MRI reading substantially improves csPCa detection and can reduce unnecessary biopsies in a screening setting. High-quality imaging, standardized protocols, and experienced reading should be considered essential components of future MRI-based screening strategies. TRIAL REGISTRATION: The trial is registered with the ISRCTN (International Randomized Controlled Trial Number) registry, registration number ISRCTN37591328, and can be accessed at https://www.isrctn.com/ISRCTN37591328. The study protocol can be accessed at doi: 10.1016/j.eururo.2013.05.022.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Boschheidgen M, Al-Monajjed R, Schlemmer HP, et al. MRI Quality and Reader Experience in Organized Prostate Cancer Screening: Insights from the PROBASE Trial. Eur Urol Oncol. 2026. PMID: 42225542. doi:10.1016/j.euo.2026.05.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。